1 Report Overview

• 1.1 Study Scope
• 1.2 Market Analysis by Type
  • 1.2.1 Global Autoimmune Drugs Market Size Growth Rate by Type: 2020 VS 2026
  • 1.2.2 Rheumatoid Arthritis (RA)
  • 1.2.3 Multiple Sclerosis (MS)
  • 1.2.4 Psoriasis
  • 1.2.5 Inflammatory Bowel Disease (IBD)
  • 1.2.6 Ankylosing Spondylitis (AS)
  • 1.2.7 Systemic Lupus Erythematosus (SLE)
• 1.3 Market by Application
  • 1.3.1 Global Autoimmune Drugs Market Share by Application: 2020 VS 2026
  • 1.3.2 Hospitals
  • 1.3.3 Homecare Settings
  • 1.3.4 Specialty Clinics
• 1.4 Study Objectives
• 1.5 Years Considered

2 Global Growth Trends

• 2.1 Global Autoimmune Drugs Market Perspective (2015-2026)
• 2.2 Global Autoimmune Drugs Growth Trends by Regions
  • 2.2.1 Autoimmune Drugs Market Size by Regions: 2015 VS 2020 VS 2026
  • 2.2.2 Autoimmune Drugs Historic Market Share by Regions (2015-2020)
  • 2.2.3 Autoimmune Drugs Forecasted Market Size by Regions (2021-2026)
• 2.3 Industry Trends and Growth Strategy
  • 2.3.1 Market Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Market Restraints

3 Competition Landscape by Key Players

• 3.1 Global Top Autoimmune Drugs Players by Market Size
  • 3.1.1 Global Top Autoimmune Drugs Players by Revenue (2015-2020)
  • 3.1.2 Global Autoimmune Drugs Revenue Market Share by Players (2015-2020)
• 3.2 Global Autoimmune Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.3 Players Covered: Ranking by Autoimmune Drugs Revenue
• 3.4 Global Autoimmune Drugs Market Concentration Ratio
  • 3.4.1 Global Autoimmune Drugs Market Concentration Ratio (CR5 and HHI)
  • 3.4.2 Global Top 10 and Top 5 Companies by Autoimmune Drugs Revenue in 2019
• 3.5 Key Players Autoimmune Drugs Area Served
• 3.6 Key Players Autoimmune Drugs Product Solution and Service
• 3.7 Date of Enter into Autoimmune Drugs Market
• 3.8 Mergers & Acquisitions, Expansion Plans

4 Autoimmune Drugs Breakdown Data by Type (2015-2026)

• 4.1 Global Autoimmune Drugs Historic Market Size by Type (2015-2020)
• 4.2 Global Autoimmune Drugs Forecasted Market Size by Type (2021-2026)

5 Autoimmune Drugs Breakdown Data by Application (2015-2026)

• 5.1 Global Autoimmune Drugs Historic Market Size by Application (2015-2020)
• 5.2 Global Autoimmune Drugs Forecasted Market Size by Application (2021-2026)

6 North America

• 6.1 North America Autoimmune Drugs Market Size (2015-2026)
• 6.2 North America Autoimmune Drugs Market Size by Type (2015-2020)
• 6.3 North America Autoimmune Drugs Market Size by Application (2015-2020)
• 6.4 North America Autoimmune Drugs Market Size by Country (2015-2020)
  • 6.4.1 United States
  • 6.4.2 Canada

7 Europe

• 7.1 Europe Autoimmune Drugs Market Size (2015-2026)
• 7.2 Europe Autoimmune Drugs Market Size by Type (2015-2020)
• 7.3 Europe Autoimmune Drugs Market Size by Application (2015-2020)
• 7.4 Europe Autoimmune Drugs Market Size by Country (2015-2020)
  • 7.4.1 Germany
  • 7.4.2 France
  • 7.4.3 U.K.
  • 7.4.4 Italy
  • 7.4.5 Russia
  • 7.4.6 Nordic
  • 7.4.7 Rest of Europe

8 China

• 8.1 China Autoimmune Drugs Market Size (2015-2026)
• 8.2 China Autoimmune Drugs Market Size by Type (2015-2020)
• 8.3 China Autoimmune Drugs Market Size by Application (2015-2020)
• 8.4 China Autoimmune Drugs Market Size by Region (2015-2020)
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 South Korea
  • 8.4.4 Southeast Asia
  • 8.4.5 India
  • 8.4.6 Australia
  • 8.4.7 Rest of Asia-Pacific

9 Japan

• 9.1 Japan Autoimmune Drugs Market Size (2015-2026)
• 9.2 Japan Autoimmune Drugs Market Size by Type (2015-2020)
• 9.3 Japan Autoimmune Drugs Market Size by Application (2015-2020)
• 9.4 Japan Autoimmune Drugs Market Size by Country (2015-2020)
  • 9.4.1 Mexico
  • 9.4.2 Brazil

10 Southeast Asia

• 10.1 Southeast Asia Autoimmune Drugs Market Size (2015-2026)
• 10.2 Southeast Asia Autoimmune Drugs Market Size by Type (2015-2020)
• 10.3 Southeast Asia Autoimmune Drugs Market Size by Application (2015-2020)
• 10.4 Southeast Asia Autoimmune Drugs Market Size by Country (2015-2020)
  • 10.4.1 Turkey
  • 10.4.2 Saudi Arabia
  • 10.4.3 UAE
  • 10.4.4 Rest of Middle East & Africa

11 Key Players Profiles

• 11.1 Eli Lilly
  • 11.1.1 Eli Lilly Company Details
  • 11.1.2 Eli Lilly Business Overview
  • 11.1.3 Eli Lilly Autoimmune Drugs Introduction
  • 11.1.4 Eli Lilly Revenue in Autoimmune Drugs Business (2015-2020))
  • 11.1.5 Eli Lilly Recent Development
• 11.2 GSK
  • 11.2.1 GSK Company Details
  • 11.2.2 GSK Business Overview
  • 11.2.3 GSK Autoimmune Drugs Introduction
  • 11.2.4 GSK Revenue in Autoimmune Drugs Business (2015-2020)
  • 11.2.5 GSK Recent Development
• 11.3 AbbVie
  • 11.3.1 AbbVie Company Details
  • 11.3.2 AbbVie Business Overview
  • 11.3.3 AbbVie Autoimmune Drugs Introduction
  • 11.3.4 AbbVie Revenue in Autoimmune Drugs Business (2015-2020)
  • 11.3.5 AbbVie Recent Development
• 11.4 Johnson & Johnson
  • 11.4.1 Johnson & Johnson Company Details
  • 11.4.2 Johnson & Johnson Business Overview
  • 11.4.3 Johnson & Johnson Autoimmune Drugs Introduction
  • 11.4.4 Johnson & Johnson Revenue in Autoimmune Drugs Business (2015-2020)
  • 11.4.5 Johnson & Johnson Recent Development
• 11.5 Biogen
  • 11.5.1 Biogen Company Details
  • 11.5.2 Biogen Business Overview
  • 11.5.3 Biogen Autoimmune Drugs Introduction
  • 11.5.4 Biogen Revenue in Autoimmune Drugs Business (2015-2020)
  • 11.5.5 Biogen Recent Development
• 11.6 Amgen
  • 11.6.1 Amgen Company Details
  • 11.6.2 Amgen Business Overview
  • 11.6.3 Amgen Autoimmune Drugs Introduction
  • 11.6.4 Amgen Revenue in Autoimmune Drugs Business (2015-2020)
  • 11.6.5 Amgen Recent Development
• 11.7 Pfizer
  • 11.7.1 Pfizer Company Details
  • 11.7.2 Pfizer Business Overview
  • 11.7.3 Pfizer Autoimmune Drugs Introduction
  • 11.7.4 Pfizer Revenue in Autoimmune Drugs Business (2015-2020)
  • 11.7.5 Pfizer Recent Development
• 11.8 Roche
  • 11.8.1 Roche Company Details
  • 11.8.2 Roche Business Overview
  • 11.8.3 Roche Autoimmune Drugs Introduction
  • 11.8.4 Roche Revenue in Autoimmune Drugs Business (2015-2020)
  • 11.8.5 Roche Recent Development
• 11.9 Baxter
  • 11.9.1 Baxter Company Details
  • 11.9.2 Baxter Business Overview
  • 11.9.3 Baxter Autoimmune Drugs Introduction
  • 11.9.4 Baxter Revenue in Autoimmune Drugs Business (2015-2020)
  • 11.9.5 Baxter Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

• 13.1 Research Methodology
  • 13.1.1 Methodology/Research Approach
  • 13.1.2 Data Source
• 13.2 Disclaimer

Global Autoimmune Drugs Scope and Market Size
Autoimmune Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Autoimmune Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

Market segment by Type, the product can be split into
Rheumatoid Arthritis (RA)
Multiple Sclerosis (MS)
Psoriasis
Inflammatory Bowel Disease (IBD)
Ankylosing Spondylitis (AS)
Systemic Lupus Erythematosus (SLE)

Market segment by Application, split into
Hospitals
Homecare Settings
Specialty Clinics

Based on regional and country-level analysis, the Autoimmune Drugs market has been segmented as follows:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa

In the competitive analysis section of the report, leading as well as prominent players of the global Autoimmune Drugs market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
The key players covered in this study
Eli Lilly
GSK
AbbVie
Johnson & Johnson
Biogen
Amgen
Pfizer
Roche
Baxter